Marco Mancini

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Late appearance of JAK2 mutated polycythaemia vera in a patient with typical chronic myeloid leukaemia on imatinib: Speculations about role of therapeutic pressure and of secondary genetic events.

Late appearance of JAK2 mutated polycythaemia vera in a patient with typical chronic myeloid leukaemia on imatinib: Speculations about role of therapeutic pressure and of secondary genetic events.

Journal: Leukemia research

Published: January 10, 2023

A predictive decision support system for coronavirus disease 2019 response management and medical logistic planning.

A predictive decision support system for coronavirus disease 2019 response management and medical logistic planning.

Journal: Digital health

Published: June 21, 2022

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?

Journal: Journal of clinical medicine

Published: March 01, 2022

Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial.

Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial.

Journal: American journal of hematology

Published: February 20, 2022

Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.

Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.

Journal: American journal of hematology

Published: April 02, 2021

Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience.

Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience.

Journal: Leukemia & lymphoma

Published: March 16, 2021

Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort.

Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort.

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 27, 2020

Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance.

Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance.

Journal: Leukemia & lymphoma

Published: September 02, 2020

Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.

Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.

Journal: Annals of hematology

Published: May 28, 2020

Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment.

Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment.

Journal: Hematological oncology

Published: October 05, 2019

Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.

Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.

Journal: Oncology research and treatment

Published: March 25, 2019

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.

Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.

Journal: Annals of hematology

Published: March 03, 2019

Showing 1-12 of 36

Last Updated: 09/26/2026